Navigation Links
The Latest Preventative Treatment Option for Prostate Cancer

In a recent study researchers say they have found that the drug toremifene, also known as Fareston, used to treat breast cancer // decreased patients' cancer incidence after 12 months of treatment. All dose levels were found to have some impact, but the 20-milligram dose had the greatest effect.

514 patients in the study had high-grade prostatic intraepithelial neoplasia, characterized by abnormal cells in the lining of the prostate ducts. Patients either received a placebo or a daily dose of toremifene in a 20-milligram, 40-milligram, or 60-milligram amount. Results from 12-month biopsies show a 48-percent reduction in prostate cancer incidence for patients taking the 20-milligram dose of toremifene compared to those on placebo.

Researchers in the current study say: "With no effective treatment options available, doctors and patients often feel defenseless against the onset of prostate cancer. Fortunately, these results offer a promising new preventative approach to prostate treatment. A chemopreventive agent like toremifene is a first step toward the possibility of stopping prostate cancer before it starts and gives patients and doctors a chance to fight this pervasive disease."
'"/>




Page: 1

Related medicine news :

1. Latest device for identifying Melanomas
2. Latest discovery on Autism
3. Latest device for cardiac revival under test
4. Latest technique for asthma treatment
5. Latest drug shows promise in multiple myeloma
6. Latest Findings On The Deadly Disease - SARS
7. Latest Tumor Classification More Informative
8. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
9. A Latest Study Links Fish To Stroke
10. Enhanced Gene Therapy Outcomes Following Latest Revolution And Refinement
11. Lovers Latest Hang Outs – Railway Platform

Post Your Comments:
(Date:11/24/2009)...atory consulting firm Emergo Group recently survey...ors and industry service providers about the state...nd their outlook for 2010. , ...bal medical device regulatory consulting firm Em...nd IVD manufacturers, distributors and industry se...
(Date:11/24/2009)... be coupled with Stem Cell Therapy. , ...09 -- Entest Biomedical, Inc. (OTCBB: ENTB) anno...ufacturer of lasers regarding the development of a...Entest and used in conjunction with several stem c... These therapies are aimed at increasing efficacy ...
(Date:11/24/2009)...will be offering a free online seminar (webinar) o...d certified ophthalmologist and pioneer in LASIK s... , (Vocus) November 23, 20...nar on LASIK Vision Correction – which can b...is free to anyone attending., , ,The webinar is pr...
(Date:11/24/2009)...-USFarms,Inc.,(PinkSheets:USFM)adiversifiedsupplie...nounceithasreceivedformalcertificationapprovalbyth...M)Juiceproduct. ,, YanSkwara,CEOofUSFarms,Inc.s...edthecertificationprocesswiththeAmericanVegetarian...goaloftheAVAistoprovideawidelyrecognizedcertificat...
(Date:11/24/2009)...CountyHeathcare(LCH)isasmallhealthsystemontherugge...munities,employingmorethan1,200fullandpart-timepeo...uccessfulbackup,you,renotdoingyourjob,"saysBrooksB...hecasewithmanyhospitalsinMaine,budgetsareextremely...rotecthismissioncriticalsystems.Hedrewupaplan,went...
Breaking Medicine News(10 mins):Health News:Medical Device Industry Positive About 2010 – Survey 2Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Free LASIK Surgery Webinar 2Health News:Free LASIK Surgery Webinar 3Health News:Free LASIK Surgery Webinar 4Health News:US Farms, Inc. Receives American Vegetarian Association Certification Approval for Aloe365(TM) Juice Product 2Health News:Replay 4 Customer Takes Risk, Fights for Budget to Protect Information Systems 2
... Delhi Cabinet today cleared the business model fo...ary Sciences (ILBS) being set up in the capital. /...eeting chaired by Chief Minister Sheila Dikshit wo...edical equipment would be borne by Delhi Governmen...
... Zolpidem is usually used to treat insomnia. T...ied for a period of six months by South African re...eveal that they are in a condition where keeping e... Zolpidem was given to the patients every morn...
... There appears to be a ray of hope for men, who ar...on with no remedy from available treatment measure...where the animal’s very own penile cells were used...s were introduced with a graft made from manufactu...
... Scott and Nicola Smith of Leicester parents of si...ffering from the incurable disorder Adrenoleukodys...ading to hear came true yesterday with reports ind...e nearly always male who lose sight, hearing, and ...
... The results of a new study shows that people with...to develop heart failure in middle age, the result...ome means a cluster of conditions, including obesi...disease, stroke and diabetes. A team of Swedish re...
... Researchers from the University of Florida announ...hickens with a disease that otherwise would have l...e researchers hope that the gene therapy may one d... the research, which delayed the onset of blindnes...
Other Medicine News:Health News:A Mother Passes On A Rare, Terminal Brain Disease To Her Three Children 2Health News:Gene Therapy May Help Restore Sight In Congenital blindness 2
(Date:11/24/2009)...v.24/PRNewswire/--AFOXThanksgivingDaytelevisionspe....S.remindsviewersthattheholidaysareatimetobegratef...rallthosewhofightthatbattleeachdayassurvivors,care...hehistoricreturntotheiceofcancersurvivorsScottHami...on-JohnandDavidFosterwhowillperform"HopeisAlwaysHe...
(Date:11/23/2009)...,Nov.23/PRNewswire-USNewswire/--FebeDurango-Rueda,...oparticipatinginaschemetodefraudtheExport-ImportBa...announcedAssistantAttorneyGeneraloftheCriminalDivi....GratacosoftheEx-ImBank,OfficeoftheInspectorGenera...obertsinU.S.DistrictCourtinWashingtontoaone-countc...
(Date:11/23/2009)...a.,Nov.23/PRNewswire-FirstCall/--Immucor,Inc.(Nasd...ment-reagentsystemstothebloodtransfusionindustry,t...Jaffray21stAnnualHealthCareConferenceinNewYork,NYw...TheCompany,spresentationisscheduledforTuesday,Dece...ntationwillbeavailablethroughthe"AboutUs--Investor...
Breaking Medicine Technology:FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 2FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 3Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 1Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 3Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 1Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 1Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 3
...SAN MATEO, Calif., Oct. 3 Anthera Pharmaceuticals...developing,anti-inflammatory therapeutics for chro...y the completion of enrollment and patient dosing ...d, A-002 for stable coronary,artery disease. Data ...f,the year. "We are pleased with the rapid enroll...
...NEW YORK, Oct. 2 ImClone Systems Incorporated,(Na...SE: BMY ) today announced,that the U.S. Food and ...o,the ERBITUX(R) (Cetuximab) product labeling to i...epidermal growth factor inhibitor,(EGFR)-expressin...er,failure of both irinotecan- and oxaliplatin-bas...
Other Medicine Technology:Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
TPS-TL Spinal Spacer
...esorbable, osteoconductive matrix consisting of hy...ared for use in oral maxillofacial procedures as a...g Pro Osteon 200R has been FDA indicated as a bone...h bone during the healing process. Its interconnec...
O-arm Complete Multidimensional Surgical Imaging
Merlin Patient Care System
Medicine Products: